Bharatt Chowrira, PhD, JD, has been the president and chief of business and strategy at PureTech since March 2017. Prior to joining PureTech, Dr Chowrira was the president of Synlogic, Inc., a biopharmaceutical company focused on developing synthetic microbiome-based therapeutics, from September 2015 to February 2017, where he oversaw and managed corporate and business development, alliance management, financial, human resources, intellectual property and legal operations. Prior to joining Synlogic, Dr Chowrira was the chief operating officer of Auspex Pharmaceuticals Inc., from 2013 to 2015, which was acquired by Teva Pharmaceuticals in the Spring of 2015. Previously, he was president and chief executive officer of Addex Therapeutics Ltd., a biotechnology company publicly traded on the SIX Swiss Exchange, from 2011 to 2013. Prior to that, Dr Chowrira held various leadership and management positions at Nektar Therapeutics (chief operating officer), Merck & Co, or Merck (vice president), Sirna Therapeutics (general counsel; acquired by Merck) and Ribozyme Pharmaceuticals (chief patent counsel). Dr Chowrira is a member of the board of directors of Vedanta Biosciences, Inc., and Vor Biopharma, Inc. Dr Chowrira received a JD from the University of Denver’s Sturm College of Law, a PhD in molecular biology from the University of Vermont College of Medicine, an MS in molecular biology from Illinois State University and a BS in microbiology from the UAS, Bangalore, India.

Joep Muijrers, PhD, is the chief of portfolio strategy at PureTech. Dr Muijrers has two decades of experience in corporate and capital finance, specifically focused on investment, M&A, portfolio management, strategic asset allocation, financial and regulatory reporting and fundraising. Prior to joining PureTech, he was a portfolio manager and partner at LSP (Life Sciences Partners), a specialist investor group with sole focus on investing in healthcare and life sciences, in the Netherlands and in Boston. At LSP, Dr Muijrers was responsible for investing in publicly traded companies, a strategy that generated a total return in excess of 900 percent, more than twice the return of the Nasdaq Biotechnology Index during the same period (Q2 2008 – Q1 2018). Notable investments included companies that were acquired by large pharma (Ablynx, CoLucid, InterMune, Kite Pharma, NeuroDerm) and/or became leaders in their respective areas of activity (Evotec, Genmab, GW Pharmaceuticals, MorphoSys, Neurocrine). Prior to joining LSP, he held the position of director corporate finance and capital markets at Fortis Bank, currently part of ABN AMRO. Dr Muijrers is currently a member of the board of directors of Alivio Therapeutics, Inc., Entrega, Inc., Follica, Incorporated and Sonde Health, Inc. Dr Muijrers holds a PhD degree in molecular biology from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany and an MS in biochemistry from the University of Nijmegen, the Netherlands.

Daphne Zohar is the founder and chief executive officer of PureTech and a member of the board of directors. She has also served as the founding chief executive officer of a number of PureTech’s Founded Entities. A successful entrepreneur, Ms Zohar created PureTech, assembling a leading team to help implement her vision for the Company, and was a key participant in fundraising, business development and establishing the underlying programs and platforms that have resulted in PureTech’s substantial pipeline, which is comprised of 23 product candidates and one product that has been cleared by the US Food and Drug Administration. Ms Zohar has been recognized as a top leader and innovator in biotechnology by a number of sources, including EY, BioWorld, MIT Technology Review, The Boston Globe and Scientific American. She is an editorial advisor to Xconomy, a US news company.